Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. - Wikidata - awgldk - TriplyDB

Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.

Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.

http://www.wikidata.org/entity/Q34858052

about

A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease Spanish guidelines for the management of autosomal dominant polycystic kidney disease Experimental therapies and ongoing clinical trials to slow down progression of ADPKD The Treatment of Autosomal Dominant Polycystic Kidney Disease Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?Clinical utility of PKD2 mutation testing in a polycystic kidney disease cohort attending a specialist nephrology out-patient clinic.Predictors of autosomal dominant polycystic kidney disease progression A young patient with a family history of hypertension.Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry.Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease Urine osmolarity and risk of dialysis initiation in a chronic kidney disease cohort--a possible titration target?Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease.Diagnostic Algorithm in the Management of Acute Febrile Abdomen in Patients with Autosomal Dominant Polycystic Kidney Disease.Experiences and Perspectives of Polycystic Kidney Disease Patients following a Diet of Reduced Osmoles, Protein, and Acid Precursors Supplemented with Water: A Qualitative Study.Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus.Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.RBC deformability and amino acid concentrations after hypo-osmotic challenge may reflect chronic cell hydration status in healthy young men.Kidney volume and function in autosomal dominant polycystic kidney disease.Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment.Multidrug therapy for polycystic kidney disease: a review and perspective.Vasopressin: a novel target for the prevention and retardation of kidney disease?New treatments for autosomal dominant polycystic kidney disease Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials.Metabolic abnormalities in autosomal dominant polycystic kidney disease.Pharmacological management of polycystic kidney disease.Rationale for early treatment of polycystic kidney disease.An approach to cystic kidney diseases: the clinician's view.Vasopressin regulation of sodium transport in the distal nephron and collecting duct.The spectrum of autosomal dominant polycystic kidney disease in children and adolescents.Clinical Manifestation and Management of ADPKD in Western Countries.Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease.Influence of angiotensin converting enzyme (ACE) gene rs4362 polymorphism on the progression of kidney failure in patients with autosomal dominant polycystic kidney disease (ADPKD).NOS3 tagSNPs does not modify the chronic kidney disease progression in autosomal dominant polycystic kidney disease.Is Autosomal Dominant Polycystic Kidney Disease Becoming a Pediatric Disorder?Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.New treatment paradigms for ADPKD: moving towards precision medicine.Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.Angiotensinogen gene polymorphisms and progression of chronic kidney disease in ADPKD patients.

P2860

Q26798115-B4B7D9CD-4389-482A-B82C-7539A585AC61 Q26863397-96F2F3FE-AD15-4D21-96A8-E670F9816F2F Q27001230-C3B73971-07EA-4F0D-A9EB-16C00ABD6F65 Q28077060-416132F7-627A-42B3-818C-24654F8AB42B Q34094366-D5598F44-FA59-47A7-AC7D-00A899C58807 Q34366204-2BD4FD01-2624-4ECA-B4DD-ABB399EEA32F Q34427678-A72B191B-984E-4F9B-B1C8-1E5761EFADDE Q34629700-F744E9AE-5F80-4453-A4B0-2104506AA2E6 Q34978995-B8811363-A5B6-4BF4-96BB-C4CD05C6ECEE Q35126716-FE959833-04AF-406C-A1DE-2FB7A9A59682 Q35133545-BEAF7000-22A9-46CE-8940-0757740F352D Q36025651-D3159799-ABF3-420D-B63D-65AA63B098BF Q36104948-F56D1661-B6AB-4B3F-995B-82F9B17F1D34 Q36106841-48F8836C-8F3D-440F-B758-4EFC5B998058 Q36315686-634EAD5C-6F0C-46FC-80EF-38D5829B199B Q36616057-9F1B5FB8-3A88-4258-887E-2925E8DEE02C Q36741005-B7B121CD-4FE9-4415-B809-E19E5A70CB9C Q37344161-B41531B9-1A3E-4B67-8DF2-76CFD5C10079 Q37581497-1E92BDE6-FC97-43F5-AFB6-A8E7EABA68D2 Q38030726-119BB056-97C7-4524-9A27-D0C0D4530B87 Q38083427-7FCADED2-AB6E-4BD2-A387-54ADD48A9641 Q38084471-B247A438-E501-4E51-AB88-1CDA208520AB Q38099698-894DB707-5510-4DB0-BF73-F576D9B76250 Q38181599-24D64701-5E5A-4560-8174-6C70879099FA Q38192854-1849E632-C3CE-4BBA-BC13-F30899FD31ED Q38199755-91C770D5-A4FC-47B9-8D2B-9D280B4BA23C Q38229242-7784C340-6A76-4680-AD45-EDE438A9319B Q38255292-9DD22620-E073-4DB2-98D4-4A59A09FEA74 Q38515104-C64020E9-8542-4D79-AA72-62C1205C1053 Q38795233-F9348599-2E1E-4ECA-A5EA-5D8071894D27 Q39030254-65CFAE2A-C01F-40C0-96FA-37CA50E4DC82 Q41003622-D5B51983-6EB9-42E2-988F-61364DDB0BBE Q41661652-3023A23C-F20F-4AD5-8C0F-3E69D782DB1D Q44624885-5D6F66ED-82D2-490B-B6C7-86C2ADB2A965 Q47344872-6BBE9AD6-7E27-439E-BED4-16262450040F Q47666190-0FD4E661-F389-4DAD-AB97-D32D0E24B100 Q49494721-15CF5EC4-2C18-4151-A76F-222CA891315B Q51001591-4DD00CC0-31C2-4410-93FA-43B3F2EE2687 Q51735152-9571BC4C-60C2-4F99-91B3-741DA5B27CF9 Q53662547-37D67C2F-0086-487E-B4F8-530D819D1082

P2860

Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.

http://www.wikidata.org/entity/Q34858052

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Potentially modifiable factors ...... ant polycystic kidney disease.

@ast

Potentially modifiable factors ...... ant polycystic kidney disease.

@en

Potentially modifiable factors ...... ant polycystic kidney disease.

@nl

type

label

Potentially modifiable factors ...... ant polycystic kidney disease.

@ast

Potentially modifiable factors ...... ant polycystic kidney disease.

@en

Potentially modifiable factors ...... ant polycystic kidney disease.

@nl

prefLabel

Potentially modifiable factors ...... ant polycystic kidney disease.

@ast

Potentially modifiable factors ...... ant polycystic kidney disease.

@en

Potentially modifiable factors ...... ant polycystic kidney disease.

@nl

P1433

Q34858052-6FD2F08A-4122-4C0F-862B-863D28E31723

P1476

Q34858052-CE1E6E8F-65BE-4810-95C1-5EAFE3CADD80

P2093

Q34858052-0858E2FB-19B7-4468-BE8F-83A636D00BBC

Q34858052-0F45B20A-C8A4-4E0D-9C1F-F9D85EAD31F7

Q34858052-0F962B8B-A4FE-4378-8B1E-3B3A7A71D072

Q34858052-22153608-3D7E-444D-8438-CD1E74DFB7F3

Q34858052-477085E2-CB23-4F60-977D-60AD27B8E017

Q34858052-7CD8EB35-E6D8-4C86-A5B1-BA2514A469B0

Q34858052-83C96FAC-3B68-4562-8B1D-04BE0B0F4C56

Q34858052-9F309883-5DB1-4795-877F-10FDDA9A6FE9

Q34858052-9FCC4407-28E1-4617-8C98-1CA7DBF0DEAC

Q34858052-C3F5C2EB-266C-4691-8B24-43B1F1710ABF

P2860

Q34858052-086C57BB-E239-4703-9821-2EF13BF3CA34

Q34858052-0D3342FA-6981-4516-B544-9CDB117C2A7F

Q34858052-1A4D69E7-8AFA-42A9-8CFB-C05AC1A44FA7

Q34858052-31BEB10D-EE29-49C8-9141-A4CED564F0FB

Q34858052-347EEC06-29AA-4B0B-9E9E-AE4B9175362C

Q34858052-3E3EB95E-0192-4A23-B8BB-099CA75556E2

Q34858052-40E443EF-30B2-471C-9BD9-BAEBBB312CFF

Q34858052-68C13ADA-B3FF-4759-A476-78C4D0D31EF3

Q34858052-72206EFE-934A-4C92-B58B-D32D3A2E64A2

Q34858052-7BBF26D0-93F1-4C14-91CD-AD0443555F50

P304

Q34858052-6FC91A89-3553-43D9-A663-FCAB2670E861

P31

Q34858052-90F71B6E-C6BE-470D-8E06-7093EA46F101

P356

Q34858052-7ED98F18-09E5-4BD3-8CAB-CA24B04FCCD0

P433

Q34858052-A7C1387F-971B-4EB1-89B6-896F43832B36

P478

Q34858052-34824B60-E2D5-4F82-979E-45A8905C3291

P50

Q34858052-4A5ED049-D9D4-4CBD-A6F7-EBFB2350C66D

Q34858052-E3C3B35D-C160-4B53-9025-D34CCAE7B8E2

P577

Q34858052-0C52322C-E90E-4AA0-8B16-969BB868C2FB

P698

Q34858052-F21237E6-6CB8-4AE8-9D17-F661960E20ED

P921

Q34858052-1C8BDF17-01B6-4489-B0D5-749E8728352C

P932

Q34858052-912BAEDF-C11F-4008-AFB5-C047E67D90F9

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Potentially modifiable factors ...... nant polycystic kidney disease

@en

P2093

Arlene B Chapman

http://www.w3.org/2001/XMLSchema#string

Bernard F King

http://www.w3.org/2001/XMLSchema#string

Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP)

http://www.w3.org/2001/XMLSchema#string

Diego Martin

http://www.w3.org/2001/XMLSchema#string

James E Bost

http://www.w3.org/2001/XMLSchema#string

Jared J Grantham

http://www.w3.org/2001/XMLSchema#string

Kyongtae T Bae

http://www.w3.org/2001/XMLSchema#string

Louis H Wetzel

http://www.w3.org/2001/XMLSchema#string

Mark E Lockhart

http://www.w3.org/2001/XMLSchema#string

Michal Mrug

http://www.w3.org/2001/XMLSchema#string

P2860

Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease

Identification of apolipoproteinA1 reduction in the polycystic kidney by proteomics analysis of the Mxi1-deficient mouse.

Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects.

Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects.

Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets.

Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease

A comprehensive review on salt and health and current experience of worldwide salt reduction programmes.

Vasopressin directly regulates cyst growth in polycystic kidney disease.

P304

640-647

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.03250410

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Marva Moxey-Mims

P577

2010-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21088290

http://www.w3.org/2001/XMLSchema#string

P921

autosomal dominant polycystic kidney disease

P932

3082424

http://www.w3.org/2001/XMLSchema#string